“Lighten This Burden of Ours”: Acceptability and Preferences Regarding Injectable Antiretroviral Treatment Among Adults and Youth Living With HIV in Coastal Kenya

Background: Long-acting injectable (LAI) antiretroviral therapy (ART) may offer persons living with HIV (PLWH) an attractive alternative to pill-based treatment options, yet acceptability data remain scant, especially in sub-Saharan Africa. Methods: We conducted 6 focus group discussions with PLWH, including key stake holder groups, and analyzed data with content analysis. Results: Initial reactions to the idea of LAI-ART were often positive. The primary advantages voiced were potential to facilitate improved adherence and alleviate the burden of daily pill-taking while avoiding inadvertent disclosure and HIV stigma. Potential side effects were a particular concern of the women. Most participants preferred clinic-based administration over self-injections at home due to concerns about safety, privacy, and potential need for refrigeration. Conclusions: LAI-ART may be acceptable in Kenya, provided injections are infrequent and delivered in a clinic setting. However, HIV stigma, fear of potential side effects, and limited clinical capacity would need to be addressed.

[1]  A. Collier,et al.  A Conjoint Analysis of the Acceptability of Targeted Long-Acting Injectable Antiretroviral Therapy Among Persons Living with HIV in the U.S. , 2019, AIDS and Behavior.

[2]  A. Collier,et al.  Acceptability of Cell and Gene Therapy for Curing HIV Infection Among People Living with HIV in the Northwestern United States: A Qualitative Study. , 2019, AIDS research and human retroviruses.

[3]  C. Correll,et al.  Patients With Early-Phase Schizophrenia Will Accept Treatment With Sustained-Release Medication (Long-Acting Injectable Antipsychotics): Results From the Recruitment Phase of the PRELAPSE Trial. , 2019, The Journal of clinical psychiatry.

[4]  A. Collier,et al.  Long-Acting Injectable Antiretroviral Treatment Acceptability and Preferences: A Qualitative Study Among US Providers, Adults Living with HIV, and Parents of Youth Living with HIV. , 2019, AIDS patient care and STDs.

[5]  E. Gutiérrez-Gutiérrez.  Preliminary , 2018, Revista Facultad de Ingeniería Universidad de Antioquia.

[6]  C. Cohen,et al.  Differentiated HIV care in sub-Saharan Africa: a scoping review to inform antiretroviral therapy provision for stable HIV-infected individuals in Kenya , 2018, AIDS care.

[7]  C. Flexner.  Antiretroviral implants for treatment and prevention of HIV infection , 2018, Current opinion in HIV and AIDS.

[8]  B. Ngwira,et al.  Effect of self-administration versus provider-administered injection of subcutaneous depot medroxyprogesterone acetate on continuation rates in Malawi: a randomised controlled trial. , 2018, The Lancet. Global health.

[9]  M. Murray,et al.  Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain , 2018, PloS one.

[10]  M. J. van der Laan,et al.  Association of Implementation of a Universal Testing and Treatment Intervention With HIV Diagnosis, Receipt of Antiretroviral Therapy, and Viral Suppression in East Africa , 2017, JAMA.

[11]  A. Cingolani,et al.  Long-acting agents for HIV infection: biological aspects, role in treatment and prevention, and patient's perspective. , 2017, The new microbiologica.

[12]  S. Rannard,et al.  Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy. , 2016, Advanced drug delivery reviews.

[13]  J. Parsons,et al.  Familiarity with and Preferences for Oral and Long-Acting Injectable HIV Pre-exposure Prophylaxis (PrEP) in a National Sample of Gay and Bisexual Men in the U.S. , 2016, AIDS and Behavior.

[14]  C. Westhoff,et al.  Injectable agents for pre-exposure prophylaxis: lessons learned from contraception to inform HIV prevention. , 2015, Current opinion in HIV and AIDS.

[15]  D. Havlir,et al.  Implementation challenges for long-acting antivirals as treatment , 2015, Current opinion in HIV and AIDS.

[16]  Yunbing Wang,et al.  Evolution of implantable and insertable drug delivery systems. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[17]  D. Kimani,et al.  Medical Injection Use Among Adults and Adolescents Aged 15 to 64 Years in Kenya: Results From a National Survey , 2014, Journal of acquired immune deficiency syndromes.

[18]  J. Meza,et al.  Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients. , 2013, Nanomedicine.

[19]  K. Rivet Amico,et al.  A situated-Information Motivation Behavioral Skills Model of Care Initiation and Maintenance (sIMB-CIM): An IMB Model Based Approach to Understanding and Intervening in Engagement in Care for Chronic Medical Conditions , 2011, Journal of health psychology.

[20]  B. Hirschel,et al.  HIV drugs for treatment, and for prevention , 2010, The Lancet.

[21]  Hsiu-Fang Hsieh,et al.  Three Approaches to Qualitative Content Analysis , 2005, Qualitative health research.